NEW YORK (GenomeWeb News) – Diaxonhit today announced an agreement with Boehringer Ingelheim to discover and characterize novel splice variants that potentially could be therapeutic targets for oncology.

Paris-based Diaxonhit will use its SpliceArray discovery platform to identify potential targets and then build a database of specific splice variants. Boehringer Ingelheim has the option to buy the rights to research, develop, and commercialize any targets discovered by Diaxonhit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.